Delivery Order SPE2DB24D9105-SPE2DB25FBYVR
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $34,061.31 to DMS Pharmaceutical Group Inc. for the supply of Lenvima 8 mg daily dose tablets (60-count). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge location with an ultimate completion date of October 6, 2025. This award was made without a set-aside designation, and the contract was...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 8 mg daily dose tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $11,353.77, was awarded on September 10, 2025, with an ultimate completion date of October 1, 2025. The contract contains no set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The Defense Logistics Agency awarded a delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 14 mg daily dose medication (60-count supply). This firm fixed-price delivery order, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a tactical fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 12 mg daily dose in 90-count quantities. The award, issued on August 7, 2025, with an ultimate completion date of August 28, 2025, utilizes firm fixed-price terms without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. for LENVIMA 20 mg daily dose (60-count supply) valued at $11,353.77 on August 21, 2025, with completion expected by September 12, 2025. This firm fixed-price delivery order was awarded without set-aside designation to the Park Ridge, Illinois-based woman-owned small business pharmaceutical wholesaler. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $22,707.56 to DMS Pharmaceutical Group Inc. for the supply of LENVIMA 10 mg daily dose (30-count) medication. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without set-aside designation. The delivery order is scheduled for completion by September 22, 2025, and represents a discrete fulfillment under the company's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for LENVIMA 8 mg daily dose tablets (60-count supply) with a ceiling value of $11,353.77. This firm fixed-price delivery order, awarded on August 28, 2025, with an ultimate completion date of September 19, 2025, represents a procurement of a specialized oncology medication. The contract carries no set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,353.77 by the Defense Logistics Agency on September 9, 2025, for the supply of Lenvima 10 mg daily dose tablets (30-count packaging). The contract carries an ultimate completion date of September 30, 2025, and includes no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's existing Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $11,353.77 by the Defense Logistics Agency on August 22, 2025, for the supply of Lenvima 8 mg daily dose tablets (60-count). This firm fixed-price delivery order is scheduled for completion by September 15, 2025, with performance taking place at the vendor's Park Ridge location. The award was made without a set-aside designation, reflecting...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,353.77 by the Defense Logistics Agency (DLA) on September 16, 2025. The contract calls for the delivery of Lenvima 20 mg daily dose tablets in quantities of 60 units, with an ultimate completion date of October 7, 2025. This delivery order was issued without a set-aside designation, leveraging the contractor's competitive...
- SPE2DB24D9105Indefinite Delivery Contract
- SPE2DB24D9105-SPE2DB25FBYVRDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc. for the supply of Lenvima 8 mg daily dose tablets (60-count) with an ultimate completion date of October 7, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under the company's existing Indefinite Delivery Contract with the DLA's SPE2DB program, a $500 million blanket procurement vehicle valid through November 2026 that enables the agency to procure pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide. Lenvima is a targeted cancer therapy used in the treatment of various malignancies, and this delivery order fulfills a specific pharmaceutical need within the DLA's broader medical supply operations. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its robust portfolio of pharmaceutical product deliveries, which encompass branded and generic prescription drugs, biologics, and medical consumables. The company's consistent success in competing for DLA contracts demonstrates its capability to reliably distribute specialized pharmaceutical products to military health facilities across the United States and internationally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 9/16/25 |